HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage company advancing novel therapies to treat acute and chronic liver disease, announced that...
XL-protein GmbH, a pioneer in the area of biopolymers for pharmacokinetic optimization, announced that it has entered into a worldwide License, Dev...
SynaptixBio, the only company licensed to commercialise a treatment for a rare, deadly disease, says the drug could halt disease progression and even rever...
Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule all...
Sanofi is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025-2026 respiratory syncytial virus (RSV)...
Now approved in the EU, Duvyzat offers an important treatment option for delaying Duchenne muscular dystrophy (DMD) disease progression Duvyzat is an ...
Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75% or greater improvement in overall dise...
Valneva SE , a specialty vaccine company, announced positive six-month antibody persistence and safety data for its Phase 2 clinical trial evaluatin...
Collaboration leverages cutting-edge reformulation expertise to generate cross-species insights, fast-track human clinical programs, and seeks to captu...
The US Food and Drug Administration (FDA) has granted orphan drug designation to rilzabrutinib, a novel, advanced, oral, reversible Bruton's tyrosine kin...
Axplora, a global leader in API small molecule and ADC (antibody-drug conjugate) manufacturing, is proud to announce that its Chasse-sur-Rhône CDMO...
CERo Therapeutics Holdings, Inc,an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that d...
Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a significant leadership transition with the appointment ...
Nxera Pharma Co., Ltd. announces that it has achieved a development milestone under its multi-target collaboration and license agreement with Eli Lilly a...
© 2025 Biopharma Boardroom. All Rights Reserved.
